IDO Pathway and Cancer

**Key Immuno-Oncology Target**

- IDO (indoleamine 2,3-dioxygenase) is an intracellular enzyme that regulates immune responses and when the pathway is active, results in an immuno-suppressive phenotype rather than an activated anti-tumor phenotype\(^1\)
- Tumors hijack the IDO pathway, a normal part of the immune system, to facilitate immune escape\(^2\)
- Used in combination with other cancer therapies, IDO pathway inhibitors are being evaluated in multiple tumor types to potentially improve outcomes for patients with cancer

\(^1\) Mertz, R. *Oncimmunology*. 2012;1(9):1460-1468.

**Targeting the IDO Pathway**

**Two Strategies for Inhibition**

- **Indoximod**
  - Acts directly on immune cells to reverse IDO pathway mediated suppression

- **Navoximod (GDC-0919)**
  - Direct IDO enzymatic inhibitor, blocks tryptophan metabolism\(^1,2\)

- Available data indicate similar activity with both approaches\(^3\)

\(^1\) Mautino, M. *AACR* 2013. Abstract 491.
\(^3\) Mautino, M. *AACR* 2013. Abstract 5023.